Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons

Prashant Kumar Modi*, Narayana Komaravelli*, Neha Singh, and Pushkar Sharma
Eukaryotic Gene Expression Laboratory, National Institute of Immunology, New Delhi 110067, India

ABSTRACT In response to neurotoxic signals, postmitotic neurons make attempts to reenter the cell cycle, which results in their death. Although several cell cycle proteins have been implicated in cell cycle–related neuronal apoptosis (CRNA), the molecular mechanisms that underlie this important event are poorly understood. Here, we demonstrate that neurotoxic agents such as β-amyloid peptide cause aberrant activation of mitogen-activated kinase kinase (MEK)–extracellular signal-regulated kinase (ERK) signaling, which promotes the entry of neurons into the cell cycle, resulting in their apoptosis. The MEK-ERK pathway regulates CRNA by elevating the levels of cyclin D1. The increase in cyclin D1 attenuates the activation of cyclin-dependent kinase 5 (cdk5) by its neuronal activator p35. The inhibition of p35-cdk5 activity results in enhanced MEK-ERK signaling, leading to CRNA. These studies highlight how neurotoxic signals reprogram and alter the neuronal signaling machinery to promote their entry into the cell cycle, which eventually leads to neuronal cell death.

INTRODUCTION

By definition, postmitotic neurons exit the cell cycle and are arrested in the G0 state. However, under neurotoxic stress and in neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease, a strong correlation between cell cycle reentry and neuronal apoptosis has been observed (Herrup and Busser, 1995; Herrup and Yang, 2007; Herrup, 2010; Hoglinger et al., 2007). Neurotoxic agents such as β-amyloid 1-42 peptide (Aβ42) or DNA-damaging agents reactivate the cell cycle machinery of neurons, resulting in their S-phase entry, which is indicated by DNA replication and an increase in the levels of S-phase markers such as proliferating cell nuclear antigen (PCNA). The alteration in levels or the activity of cell cycle proteins such as cyclins, cyclin-dependent kinases (cdks), and cdk inhibitors may contribute to this process. For instance, levels of cyclin D1, activity of cdk4, and phosphorylation of retinoblastoma protein (Rb) are enhanced in response to trophic factor withdrawal or neurotoxic agents (Park et al., 1998, 2000a,b; Giovanni et al., 1999; Ino and Chiba, 2001). In addition, cdk inhibitors and other cell cycle blockers attenuate cell cycle–related neuronal apoptosis (CRNA; Park et al., 1997a,b).

The molecular mechanisms that cause cell cycle reentry and control events such as aberrant expression of cell cycle proteins such as cyclin D1 are poorly understood. Cyclin D1 is a key regulator of the G1–S transition as it activates cdk4, which phosphorylates Rb protein. As a result, Rb protein dissociates from EZF1, which in turn facilitates the transcription of genes needed for S-phase progression. The increased expression of cyclin D1 in response to various neurotoxic agents is implicated in neuronal apoptosis (Kranenburg et al., 1996; Sumrejkanchanakit et al., 2003; Malik et al., 2008). In addition, its nuclear localization correlates well with neuronal cell

*These authors contributed equally to this work.

N.K., P.K.M, and N.S. designed experiments, performed research, interpreted data, and helped in manuscript preparation. P.S. designed experiments, interpreted data, and was involved in manuscript preparation.

Address correspondence to: Pushkar Sharma (pushkar@niim.res.in, pushkar@niim.ac.in).

Abbreviations used: Aβ1-42, β-amyloid 1-42 peptide; Aβ1-42rev, control peptide with reverse sequence of Aβ1-42; AD, Alzheimer’s disease; BrdU, 5-bromo-2-deoxyuridine; cdk, cyclin-dependent kinase; CRNA, cell cycle–related neuronal apoptosis; ERK, extracellular signal-regulated kinase; GFP, green fluorescent protein; IP, immunoprecipitate; MEK, mitogen-activated kinase kinase; NGF, nerve growth factor; PCNA, proliferating cell nuclear antigen; PC12, rat pheochromocytoma cell; STAT3, signal transducer and activator of transcription 3; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

© 2012 Modi et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).

“The American Society for Cell Biology®,” “The American Society for Cell Biology,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society of Cell Biology.

This article was published online ahead of print in MBoC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E12-02-0125) on July 25, 2012.

The molecular mechanisms that cause cell cycle reentry and control events such as aberrant expression of cell cycle proteins such as cyclin D1 are poorly understood. Cyclin D1 is a key regulator of the G1–S transition as it activates cdk4, which phosphorylates Rb protein. As a result, Rb protein dissociates from EZF1, which in turn facilitates the transcription of genes needed for S-phase progression. The increased expression of cyclin D1 in response to various neurotoxic agents is implicated in neuronal apoptosis (Kranenburg et al., 1996; Sumrejkanchanakit et al., 2003; Malik et al., 2008). In addition, its nuclear localization correlates well with neuronal cell
death (Sumrejkananchanakij et al., 2003). Therefore the understanding of cyclin D1 regulation in CRNA may provide useful insights into this important phenomenon.

Although the mitogen-activated kinase kinase (MEK)–extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase pathway is important for neuronal survival (Ginty et al., 1994; Bonni et al., 1999; Sharma et al., 2007), the hyperactivation or aberrant activation of this pathway caused by neurotoxic agents can lead to neuronal apoptosis (Stanciu et al., 2000; Subramaniam et al., 2004; Chong et al., 2006). We report that the aberrant activation of the MEK-ERK MAP kinase pathway controls cyclin D1 expression and forces neurons into the S phase, resulting in CRNA. Cyclin D1, in turn, prevents the activation of cyclin dependent kinase 5 (cdk5) by its neuronal cyclin-like activator p35. Cdk5 is an atypical cdk, which controls a wide variety of neuronal functions, including neuronal migration (Ohshima et al., 1996), differentiation, and survival (Dhawan and Tsai, 2001). Cdk5 is regulated by cyclin-like regulators p35 and p39, which are expressed in the brain and are essential for cdk5 function (Ko et al., 2001). The conversion of its activator p35 to p25 is considered to be one of the reasons for cdk5 deregulation and activation in situations such as Alzheimer’s disease (Patrick et al., 1999). Recent studies have suggested that cdk5 may be important for cell cycle arrest of postmitotic neurons (Zhang et al., 2008), and Aβ42 alters the localization of cdk5, resulting in neuronal cell cycle reentry (Zhang et al., 2010; Zhang and Herrup, 2011). The present work suggests that deregulation of p35-cdk5 by cyclin D1 may contribute to aberrant MEK-ERK signaling, which possibly provides an explanation for the role of cdk5 in CRNA.

When cortical neurons (Figure 1A and Supplemental Figure S1, A and C) or neuronal PC12 cells (see discussion of Figure 5B later in the paper) were treated with Aβ42, a significant increase in the levels of the phosphorylated form of ERK1/2 was observed in comparison to the untreated cells. The increase in ERK1/2 phosphorylation was at regulatory MEK1/2 target sites, and therefore these results were indicative of hyperactivated MEK-ERK. The treatment with U0126, a specific MEK inhibitor, attenuated the increase in cyclin D1, as well as in PCNA levels, suggesting that the neuronal cell cycle progression was blocked upon inhibition of MEK-ERK signaling (Figures 1 and 3A [later in the paper] and Supplemental Figure S1, A and C). In addition, the levels of the cleaved form of caspase 3, an indicator of apoptosis, were also reduced. A control peptide with reverse sequence of Aβ42 (Aβ42rev) did not cause any significant changes (Supplemental Figure S1C). A time-course experiment in which neurons were treated with Aβ42 for 2–48 h revealed an increase in phospho-ERK levels within 2 h of treatment, accompanied by the expression of cyclin D1, which was followed by PCNA expression in the next 2–4 h. Interestingly, significant levels of cleaved caspase 3, which indicate apoptosis, were observed only after ~24 h of treatment (Supplemental Figure S1A). These results indicated that the neurons make attempts to first enter the cell cycle or S phase, which is followed by apoptosis after a few hours.

Next we probed whether MEK-ERK signaling was responsible for CRNA. To this end, we treated cortical neurons with Aβ42 (Figure 2A) and labeled them with 5-bromo-2'-deoxyuridine (BrdU), followed by a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay to detect DNA replication and cell death, respectively. A significant number of neurons were both BrdU and TUNEL positive, which was a strong indication that these cells

**RESULTS**

Aβ42 peptide causes aberrant MEK-ERK signaling, which results in neuronal cell cycle reentry and apoptosis

One of the hallmarks of Alzheimer’s disease (AD) is the altered cleavage of amyloid precursor protein that leads to the generation of the 42-amino acid Aβ42 peptide. The neurotoxic oligomeric form of Aβ42 is a major constituent of amyloid plaques (Selkoe, 1998) and is also known to induce cell cycle reentry of neurons (Copani et al., 1999; Yang et al., 2001; Herrup and Yang, 2007). The treatment of cortical neurons (Figure 1A and Supplemental Figure S1, A and C) or nerve growth factor (NGF)-differentiated neuronal rat pheochromocytoma (PC12) cells (see discussion of Figure 3A later in the paper) with Aβ42 led to an increase in the levels of cleaved caspase 3, which was indicative of apoptosis. A corresponding increase in the levels of the S-phase marker PCNA and cyclin D1 (Figures 1 and 3A [later in the paper] and Supplemental Figure S1, A and C) and enhanced DNA replication (discussed later) were indicative of attempts of neurons to enter the cell cycle. Because MEK-ERK signaling is important for neuronal survival and death (Bonni et al., 1999; Chong et al., 2006), we explored the involvement of this MAP kinase pathway.

**FIGURE 1:** Aβ42 induces aberrant MEK-ERK signaling and cyclin D1 expression in cortical neurons. (A) Rat cortical neurons were treated with Aβ42 peptide for 48 h with DMSO (Ctrl) or 10 μM U0126. Cell lysates were prepared, followed by Western blotting with indicated antibodies. Because a time-course experiment suggested that cell death was evident 24–48 h posttreatment (Supplemental Figure S1A), treatments were performed for this duration. A representative of more than three independent experiments is shown. (B) The quantification of phospho-ERK and caspase 3 levels in experiments such as the one described in A and Supplemental Figure S1C was done. Densitometry of phospho-ERK and cleaved caspase 3 bands was performed, which was normalized with respect to total ERK and GAPDH levels, respectively. The fold change in phospho-ERK levels with respect to untreated cells is illustrated. The mean of three independent experiments is shown, and error bars represent SEM.

**REFERENCES**

Bonni, A., 1998, 'Cdk5 is a major constituent of amyloid plaques', Nature 396, 707–710.

Chong, J., 2006, 'NEK-ERK signaling in neuronal survival and death', Neuron 50, 1–5.

Copani, A., 2007, 'NEK-ERK signaling in neuronal survival and death', Neuron 50, 1–5.

Ginty, D.D., 1994, 'NEK-ERK signaling in neuronal survival', Neuron 50, 1–5.

Herrup, K., 2004, 'NEK-ERK signaling in neuronal survival', Neurobiol. Aging 25, 745–754.

Patrick, A., 2006, 'NEK-ERK signaling in neuronal survival', Neuron 50, 1–5.

Stanciu, C., 2000, 'NEK-ERK signaling in neuronal survival', Neuron 50, 1–5.
MEK-ERK signaling controls cyclin D1 expression via signal transducer and activator of transcription 3 during CRNA

Next we addressed whether cyclin D1 is directly involved in CRNA and investigated mechanisms by which its levels are elevated during this process. Cyclin D1 knockdown by specific small interfering RNA (siRNA) reversed the effects of Aβ42, which included the inhibition of PCNA and cleaved caspase 3 levels (Figure 3A). Furthermore, when recombinant adenovirus was used to overexpress cyclin D1 in primary neurons, an increase in the levels of mature caspase 3 and PCNA was observed (Figure 3B). Collectively these observations indicated that the hyperactivation of MEK-ERK results in an increase in cyclin D1, which may promote CRNA.

Aβ42 induces cyclin D1 levels by regulating its transcription (Supplemental Figure S1B). To gain insights into the mechanisms involved in this process, we studied the effect on cyclin D1 promoter. Aβ42 induced the promoter activity, which was prevented by U0126 (Figure 4A, first and second bars), suggesting MEK-ERK–dependent regulation. Signal transducer and activator of transcription 3 (STAT3) is known to promote cyclin D1 transcription during G1–S transition in dividing cells (Klein and Assoian, 2008). Therefore a previously described STAT3 binding site (Leslie et al., 2006) on cyclin D1 promoter was disrupted by site-directed mutagenesis. Aβ42 failed to enhance the activity of the mutant promoter (Figure 4A, third bar). Furthermore, the knockdown of STAT3 expression by a specific siRNA in neuronal PC12 cells resulted in a significant decrease in cyclin D1 levels (Figure 4B). Collectively these results suggested that STAT3 may control cyclin D1 expression in response to Aβ42.

Phosphorylation of STAT3 at S727 and Y705 is crucial for maximal transcriptional activation of STAT3 (Wen et al., 1999) and may involve several pathways, including the MAPK pathway (Ng et al., 2006; Wan et al., 2010). Aβ42 caused an increase in the phosphorylation of both S727 and Y705, which was reduced upon U0126 treatment (Figure 4C). Based on these data, it is reasonable to propose that Aβ42-induced MEK-ERK signaling may control cyclin D1 levels via STAT3 phosphorylation.

Elevated cyclin D1 levels may contribute to sustained MEK-ERK activation via a positive feedback loop. Even though Aβ42 hyperactivates the MEK-ERK MAP kinase pathway, resulting in increased cyclin D1 levels, the molecular mechanisms by which cyclin D1 contributes to CRNA remained unclear. One of the possibilities was that it influences the MEK-ERK pathway, which regulates several neuronal functions, including survival and apoptosis (Ginty et al., 1994; Bonni et al., 1999). Surprisingly, overexpression of cyclin D1 levels caused a significant enhancement

underwent S-phase entry and cell death. Strikingly, U0126 treatment resulted in a significant decrease in BrdU/TUNEL+ cells (Figure 2). Interestingly, the effect of U0126 on the number of TUNEL+ cells that did not exhibit BrdU incorporation (TUNEL+/BrdU−) was significantly less (Supplemental Figure S2B), which suggested that aberrant MEK-ERK activation may regulate CRNA and may have lesser influence on Aβ42-induced apoptosis of neurons that do not exhibit cell cycle reentry. As reported earlier (Bonni et al., 1999), we also noticed that the inhibition of MEK-ERK signaling under physiological conditions led to neuronal apoptosis, whereas the cell cycle status of neurons was almost unaltered (Supplemental Figure S2, A and B). In contrast to terminally differentiated cells, Aβ42 did not alter either the MEK-ERK signaling or cause apoptosis of dividing PC12 cells. However, U0126 treatment resulted in caspase 3 cleavage, suggesting that the MEK-ERK pathway is important for the survival of dividing cells (Supplemental Figure S6).

FIGURE 2: Aberrant MEK-ERK signaling induced by Aβ42 causes cell cycle reentry and neuronal apoptosis (CRNA). (A) Aβ42 peptide was added with DMSO or U0126 to cortical neurons, followed by incubation with BrdU. Immunofluorescence and TUNEL assays were performed to detect BrdU incorporation (red) or apoptotic (green) cells, respectively. (B) Percentage of cells that exhibited both BrdU and TUNEL staining. Mean of three experiments is shown, and error bars represent SE.

FIGURE 3: Increased levels of cyclin D1 may cause CRNA. (A) NGF-differentiated neuronal PC12 cells were transfected with cyclin D1 siRNA or a control siRNA. Subsequently, cells were incubated with Aβ42. The Western blotting of cell lysates revealed that the knockdown of cyclin D1 (i) caused a significant decrease in levels of PCNA (ii) and cleaved caspase 3 (iii), respectively. (B) Rat cortical neurons were infected with recombinant adenovirus for cyclin D1 (Ad-cyc D1) or GFP alone (Ad-GFP). After 48 h, Western blotting was performed using antibodies against PCNA and cleaved caspase 3.
addition) on p35-cdk5 activity is poorly understood. Because we found that cell death (Patrick age to p25. Aberrant activation of cdk5 by p25 may lead to the whether an increase in cyclin D1 levels regulates cdk5, which in turn CRNA downstream of cyclin D1. We explored the involvement of Next efforts were made to gain insight into events that regulate p35-dependent cdk5 activation

sustained MEK-ERK activation, which may contribute to CRNA.

tive of a positive feedback loop by which cyclin D1 may cause

cyclin D1 (Figures 1, 3, and 4), these results (Figure 5) were indica

gested that the MEK-ERK pathway promotes the expression of

in MEK-ERK activity (Figure 5A) in cortical neurons. The cell cycle reentry and cell death caused as a result of cyclin D1 overexpres

sion, which was indicated by the change in levels of PCNA (Supple

mental Figure S3) and cleaved caspase 3 levels (Figure 5A), was prevented by U0126. Furthermore, the reverse experiments re

ealed that cyclin D1 knockdown in Aβ42-treated neuronal PC12 cells caused a significant decrease in phospho-ERK levels (Figure 5B), confirming the positive effect of increased cyclin D1 expression on MEK-ERK signaling. Although the earlier observations suggested that the MEK-ERK pathway promotes the expression of cyclin D1 (Figures 1, 3, and 4), these results (Figure 5) were indicative of a positive feedback loop by which cyclin D1 may cause sustained MEK-ERK activation, which may contribute to CRNA.

Aβ42-mediated increase in cyclin D1 attenuates p35-dependent cdk5 activation

Next efforts were made to gain insight into events that regulate CRNA downstream of cyclin D1. We explored the involvement of cdk5 in this process, as it keeps the cell cycle of neurons suppressed (Cicero and Herrup, 2005; Zhang et al., 2010). We questioned whether an increase in cyclin D1 levels regulates cdk5, which in turn may have an impact on neuronal apoptosis. p35 activates cdk5 in neurons, and Aβ42 and other neurotoxic agents promote its cleavage to p25. Aberrant activation of cdk5 by p25 may lead to the hyperphosphorylation of proteins such as Tau and result in neuronal cell death (Patrick et al., 1999; Lee et al., 2000). The effect of Aβ42 on p35-cdk5 activity is poorly understood. Because we found that ii). The treatment with U0126 caused a decrease in cyclin D1 levels (Figure 6C, ii, lane 3). As a result, the amount immunoprecipitated with cdk5 was also reduced significantly (Figure 6C, ii, lane 3). The inhibitor had an opposite effect on p35-cdk5 association; the amount of cdk5 bound to p35-IP was reestablished (Figure 6C, i, lane 3), which corroborated well with the reversal in the loss of p35-cdk5 activity upon Aβ42 treatment (Figure 6B). As reported earlier (Lee et al., 2000), Aβ42 treatment caused an increase in p25 levels and total cdk5-IP-associated activity (Supplemental Figure S5A). In con

trast to p35-IP activity, cdk5-IP activity was not influenced by U0126 (Supplemental Figure S5B). Furthermore, cyclin D1 siRNA transfection was performed to ascertain whether MEK-ERK-dependent regulation of p35-cdk5 was via cyclin D1. The knockdown of cyclin D1 in Aβ42-treated neuronal PC12 cells significantly prevented Aβ42-mediated suppression of p35-cdk5 activity (Figure 6D, second vs. fourth bar). Collectively these data indicated that the increase in cyclin D1 levels as a result of Aβ42 treatment may block p35-cdk5 activation by competing with p35 for cdk5.

Overexpression of p35 reverts the effect of Aβ42 on p35-cdk5 regulation and neuronal apoptosis

We next tested whether p35 overexpression is able to revert some of the foregoing effects of Aβ42. To this end, we overexpressed p35 and p25 in neuronal PC12 cells, followed by treatment with Aβ42, and we measured the kinase activity associated with p35-IP or cdk5-IP. As observed earlier, Aβ42 treatment caused an increase in total cdk5-IP activity and a decrease in p35-IP-associated activity

FIGURE 4: Aβ42-triggered MEK-ERK signaling regulates cyclin D1 expression via STAT3.
(A) Cyclin D1 promoter or its variant with a mutation in STAT3-binding site (~984 base pair), which was fused to luciferase reporter, was transfected in rat cortical neurons, followed by treatment with Aβ42 in the presence of DMSO or U0126. After 48 h, luciferase activity was determined, and the fold change upon Aβ42 treatment is indicated. Aβ42 caused a significant increase in the activity of wild-type promoter but not of a STAT3–binding site mutant (STAT3m).
(B) Neuronal PC12 cells were transfected with siRNA against STAT3 or a control siRNA, followed by the addition of Aβ42. Western blot was performed to determine the levels of cyclin D1 as a result of STAT3 knockdown. C. Aβ42 treatment of cortical neurons was followed by Western blot with an antibody that recognizes STAT3 phosphorylated at S727 (left) or Y705 (right).
The evidence for the connection between cell cycle reentry of postmitotic neurons and neurodegeneration is very strong (reviewed in Herrup and Yang, 2007). CRNA is reported in vitro and in animal models for neurodegenerative disorders such as Parkinson’s disease (Hoglinger et al., 2007) and Alzheimer’s disease (Yang et al., 2001; Malik et al., 2008). Cell cycle proteins may play a crucial role in this process and may promote S-phase entry of neurons, which leads to cell death (Park et al., 1998, 2000a,b; Giovanni et al., 1999; Malik et al., 2008). For example, it has been demonstrated that cyclin D1 knockdown prevents CRNA in neurons from an AD mouse model (Malik et al., 2008). In this study, we described the link between cell cycle machinery and neuronal signaling pathways. Aβ42 induces hyperactivation of MEK-ERK signaling (Harper and Wilkie, 2003) and causes cell death by possibly mediating Tau hyperphosphorylation (Veeranna et al., 1998; Zheng et al., 2007). We found that an Aβ42-mediated aberrant MEK-ERK signaling pathway results in increased expression of cyclin D1 and causes S-phase entry and neuronal cell death. These results were surprising, as MEK-ERK signaling is known to promote neuronal differentiation and survival (Bonnier et al., 1999; Riccio et al., 1999) by promoting the transcription of genes important for this process (Riccio et al., 1999, 2002). The Aβ42-triggered MEK-ERK signaling promotes cyclin D1 expression, which is reminiscent of its role during cell division, in which it induces cyclin D1 expression via transcription factors such as STAT3 (Lavoie et al., 1996). STAT3 is phosphorylated in response to Aβ42 in a MEK-ERK-dependent manner and controls cyclin D1 expression. Interestingly, during neuronal differentiation STAT3 promotes cyclin D1 expression and its knockdown prevents withdrawal of neurons from the cell cycle (Ng et al., 2006). For maximal activation of STAT3, phosphorylation of both S727 and Y705 is needed (Wen et al., 1995), and we found that Aβ42 stimulates the phosphorylation of both STAT3 sites.

Cdk5 is activated by its regulators p35 and p39 in the nervous system. Although p35−/− mice survive embryonic lethality (Chae et al., 1997), they exhibit cortical migration defects like the cdk5−/− animals and also exhibit seizures and adult lethality. p35−/− p39−/− mice exhibit prenatal lethality and other features of cdk5−/− animals. However, p39−/− animals do not reveal any significant abnormalities, suggesting that p39 may compensate for some but not all the functions of p35 (Ko et al., 2001). Cdk5 is involved in controlling both neuronal survival and death (Cheung and Ip, 2004; Hisanaga and Endo, 2010). It cross-talks with other signaling and apoptosis pathways and prevents apoptosis of neurons (Li et al., 2002; Zheng et al., 2007; Cheung et al., 2008). Even though the kinetics of Tau phosphorylation by p35-cdk5 or p25-cdk5 is not very different (Peterson et al., 2010), the cleavage of p35 to p25 has been attributed to de-regulation of cdk5 in AD brain and Aβ42-mediated neuronal apoptosis (Patrick et al., 1999). Although p25 levels are elevated in AD brain and in Aβ42-treated cortical neurons, a significant amount of p35 expression is still observed (Lee et al., 2000; Taniguchi et al., 2001; Tandon et al., 2003). Consistent with this, we also noted the presence of p35 in cortical neurons treated with Aβ42. Although p25 causes sustained cdk5 activation (Patrick et al., 1999; Cruz et al., 2003), which may contribute to neurodegeneration, there is little evidence for the connection between cell cycle reentry of postmitotic neurons and neurodegeneration. Cell cycle proteins may play a crucial role in this process and may promote S-phase entry of neurons, which leads to cell death (Park et al., 1998, 2000a,b; Giovanni et al., 1999; Malik et al., 2008). For example, it has been demonstrated that cyclin D1 knockdown prevents CRNA in neurons from an AD mouse model (Malik et al., 2008). In this study, we described the link between cell cycle machinery and neuronal signaling pathways. Aβ42 induces hyperactivation of MEK-ERK signaling (Harper and Wilkie, 2003) and causes cell death by possibly mediating Tau hyperphosphorylation (Veeranna et al., 1998; Zheng et al., 2007). We found that an Aβ42-mediated aberrant MEK-ERK signaling pathway results in increased expression of cyclin D1 and causes S-phase entry and neuronal cell death. These results were surprising, as MEK-ERK signaling is known to promote neuronal differentiation and survival (Bonnier et al., 1999; Riccio et al., 1999) by promoting the transcription of genes important for this process (Riccio et al., 1999, 2002). The Aβ42-triggered MEK-ERK signaling promotes cyclin D1 expression, which is reminiscent of its role during cell division, in which it induces cyclin D1 expression via transcription factors such as STAT3 (Lavoie et al., 1996). STAT3 is phosphorylated in response to Aβ42 in a MEK-ERK-dependent manner and controls cyclin D1 expression. Interestingly, during neuronal differentiation STAT3 promotes cyclin D1 expression and its knockdown prevents withdrawal of neurons from the cell cycle (Ng et al., 2006). For maximal activation of STAT3, phosphorylation of both S727 and Y705 is needed (Wen et al., 1995), and we found that Aβ42 stimulates the phosphorylation of both STAT3 sites. Cdk5 is activated by its regulators p35 and p39 in the nervous system. Although p35−/− mice survive embryonic lethality (Chae et al., 1997), they exhibit cortical migration defects like the cdk5−/− animals and also exhibit seizures and adult lethality. p35−/− p39−/− mice exhibit prenatal lethality and other features of cdk5−/− animals. However, p39−/− animals do not reveal any significant abnormalities, suggesting that p39 may compensate for some but not all the functions of p35 (Ko et al., 2001). Cdk5 is involved in controlling both neuronal survival and death (Cheung and Ip, 2004; Hisanaga and Endo, 2010). It cross-talks with other signaling and apoptosis pathways and prevents apoptosis of neurons (Li et al., 2002; Zheng et al., 2007; Cheung et al., 2008). Even though the kinetics of Tau phosphorylation by p35-cdk5 or p25-cdk5 is not very different (Peterson et al., 2010), the cleavage of p35 to p25 has been attributed to de-regulation of cdk5 in AD brain and Aβ42-mediated neuronal apoptosis (Patrick et al., 1999). Although p25 levels are elevated in AD brain and in Aβ42-treated cortical neurons, a significant amount of p35 expression is still observed (Lee et al., 2000; Taniguchi et al., 2001; Tandon et al., 2003). Consistent with this, we also noted the presence of p35 in cortical neurons treated with Aβ42. Although p25 causes sustained cdk5 activation (Patrick et al., 1999; Cruz et al., 2003), which may contribute to neurodegeneration, there is little evidence for the connection between cell cycle reentry of postmitotic neurons and neurodegeneration. Cell cycle proteins may play a crucial role in this process and may promote S-phase entry of neurons, which leads to cell death (Park et al., 1998, 2000a,b; Giovanni et al., 1999; Malik et al., 2008). For example, it has been demonstrated that cyclin D1 knockdown prevents CRNA in neurons from an AD mouse model (Malik et al., 2008). In this study, we described the link between cell cycle machinery and neuronal signaling pathways. Aβ42 induces hyperactivation of MEK-ERK signaling (Harper and Wilkie, 2003) and causes cell death by possibly mediating Tau hyperphosphorylation (Veeranna et al., 1998; Zheng et al., 2007). We found that an Aβ42-mediated aberrant MEK-ERK signaling pathway results in increased expression of cyclin D1 and causes S-phase entry and neuronal cell death. These results were surprising, as MEK-ERK signaling is known to promote neuronal differentiation and survival (Bonnier et al., 1999; Riccio et al., 1999) by promoting the transcription of genes important for this process (Riccio et al., 1999, 2002). The Aβ42-triggered MEK-ERK signaling promotes cyclin D1 expression, which is reminiscent of its role during cell division, in which it induces cyclin D1 expression via transcription factors such as STAT3 (Lavoie et al., 1996). STAT3 is phosphorylated in response to Aβ42 in a MEK-ERK-dependent manner and controls cyclin D1 expression. Interestingly, during neuronal differentiation STAT3 promotes cyclin D1 expression and its knockdown prevents withdrawal of neurons from the cell cycle (Ng et al., 2006). For maximal activation of STAT3, phosphorylation of both S727 and Y705 is needed (Wen et al., 1995), and we found that Aβ42 stimulates the phosphorylation of both STAT3 sites. Cdk5 is activated by its regulators p35 and p39 in the nervous system. Although p35−/− mice survive embryonic lethality (Chae et al., 1997), they exhibit cortical migration defects like the cdk5−/− animals and also exhibit seizures and adult lethality. p35−/− p39−/− mice exhibit prenatal lethality and other features of cdk5−/− animals. However, p39−/− animals do not reveal any significant abnormalities, suggesting that p39 may compensate for some but not all the functions of p35 (Ko et al., 2001). Cdk5 is involved in controlling both neuronal survival and death (Cheung and Ip, 2004; Hisanaga and Endo, 2010). It cross-talks with other signaling and apoptosis pathways and prevents apoptosis of neurons (Li et al., 2002; Zheng et al., 2007; Cheung et al., 2008). Even though the kinetics of Tau phosphorylation by p35-cdk5 or p25-cdk5 is not very different (Peterson et al., 2010), the cleavage of p35 to p25 has been attributed to de-regulation of cdk5 in AD brain and Aβ42-mediated neuronal apoptosis (Patrick et al., 1999). Although p25 levels are elevated in AD brain and in Aβ42-treated cortical neurons, a significant amount of p35 expression is still observed (Lee et al., 2000; Taniguchi et al., 2001; Tandon et al., 2003). Consistent with this, we also noted the presence of p35 in cortical neurons treated with Aβ42. Although p25 causes sustained cdk5 activation (Patrick et al., 1999; Cruz et al., 2003), which may contribute to neurodegeneration, there is little
Aberrant MEK-ERK signaling and enhanced cyclin D1 expression prevent p35-mediated cdk5 activation. (A) Cortical neurons were infected with Ad-cyc D1 (lane 2) or Ad-GFP (lane 3). p35-IP associated cdk5 activity was determined by using a histone H1–derived peptide (PKTPKKAKKL) as substrate. Western blotting was performed with antibodies indicated against indicated proteins. The percentage activity in comparison to the control uninfected cells (100%) is shown. *p < 0.001 by ANOVA (n = 4). (B) Cortical neurons were treated with Aβ42 for 48 h in the presence of DMSO or U0126. p35 was immunoprecipitated with N-20 antibody raised against the N-terminal of p35 (Santa Cruz Biotechnology). p35-IP associated cdk5 kinase activity was determined as described for A. The percentage activity with respect to the control DMSO–treated cells (100%) is shown. Error bars reflect SE. *p < 0.01 by ANOVA (n = 4). (C) As described in B, cortical neurons were treated with Aβ42 for 48 h in the presence of DMSO (Ctrl) or U0126. p35 (i) or cdk5 (ii) was immunoprecipitated, followed by Western blotting with cdk5 (i) or cyclin D1 (ii). Whereas the amount of cdk5 associated with p35 was significantly reduced (i, lane 2) upon Aβ42 treatment, a concomitant increase in cyclin D1 binding to cdk5 (ii, lane 2) was observed. Western blotting was performed on whole-cell lysate using indicated antibodies (iii–v). (D) NGF-differentiated neuronal PC12 cells were transfected with cyclin D1 siRNA or a control scrambled siRNA, followed by treatment with Aβ42. Western blotting was performed with antibodies against cyclin D1 or cdk5. Anti-p35 antibody (N-20) was used for immunoprecipitation, and p35-IP was used to assay the associated cdk5 kinase activity as described for B. The mean percentage activity in comparison to the control siRNA–transfected cells (100%) is shown. Error bars reflect SE. ***p < 0.001 by ANOVA (n = 5).

MATERIALS AND METHODS
Plasmids, transgenic animals, siRNA, antibodies
For p35 and p25 overexpression, enhanced green fluorescent protein (EGFP) N1-p35 and EGFP N1-p25 plasmids were used. For STAT3 and cyclin D1 knockdown, 25nt duplexes were designed and custom synthesized. The sequence of siRNA against STAT3 (Ng et al., 2006) is as follows: STAT3siRNA, 5’GGAUUUUAACAUUGC-GGCACAGG 3’; STAT3 control scrambled siRNA, 5’ GGAUUUCAUUAGCCG-GCAAAGA 3’. The knockdown of cyclin D1 was achieved with siRNA of following sequence: 5’ GCGAGGAGCAGCAUGUCG-GAUG3’; cyclin D1 scrambled siRNA, 5’ GCGAGGAGCAGCAUGGAGUG 3’.

For cyclin D1 overexpression, human cyclin D1 was cloned in pAdTrack adenovirus expression vector as described later. The cyclin D1 promoter construct in PD1-Luc was a gift from Ramin Massoumi, Lund University.

The following antibodies were used for the described studies: cyclin D1 (sc-753, 1:500), PCNA (sc-56, 1:500), phospho-ERK (sc-7383, 1:500), ERK (sc-94, 1:1000), phospho-STAT3 (Ser-727; sc-80001R, 1:500), STAT3 (sc-483, 1:5000) (all Santa Cruz Biotechnology, Santa Cruz, CA), cleaved caspase 3 (9646, 1:500; Cell Signaling, Beverly, MA), actin (CP-01; Calbiochem, La Jolla, CA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-25778, 1:1000; Santa Cruz Biotechnology), GFP (2555, 1:1000; Cell Signaling), p35 (N-20, which recognizes only p35; sc-821, 1:500; Santa Cruz Biotechnology), p35/p25 (C-19, which recognizes both p35 and p25; sc-820, 1:500; Santa Cruz Biotechnology), anti-BrdU (RPN202, Amersham-Pharmacia Biotech, GE Healthcare Bio-Sciences, Piscataway, NJ), and cdk5 (sc-173, 1:500; Santa Cruz Biotechnology).

Primary neuronal and PC12 cultures
Embryonic cortical neurons were isolated from Sprague Dawley rats by using a previously published and standardized protocol.
Briefly, cortical lobes were dissected from day 18 rat embryos, and the tissue was minced finely before removing excess buffer and trypsinized with Trypsin-DNase solution. Subsequently, DMEM containing 10% fetal bovine serum (FBS) was added. The cells were gently resuspended in DMEM containing 10% FBS and 1% penicillin/streptomycin and plated on poly-l-lysine-coated 35-mm culture plates. After 12 h, cortical neurons were washed with prewarmed Tyrode’s CMF-PBS supplemented with glucose and NaHCO₃ and were maintained in Neurobasal media supplemented with B-27, N2, penicillin–streptomycin (1x), l-glutamine, and glucose. Sometimes plasmosin was also used as a precaution against mycoplasma. Typically, cortical neurons were used after 5 d in vitro for experiments.

PC12 cells were maintained in DMEM containing 10% horse serum, 5% FBS, and 1% antibiotic-antimyocytic. Neuronal PC12 cells were obtained by differentiation with NGF in low-serum media containing 1% FBS and 1% antibiotic-antimyocytic for 5–7 d.

**Treatment and transfection of cells**

The 42–amino acid version of Aβ peptide (Aβ42; rPeptide) or Aβ42rev (Tocris Biosciences, Ellisville, MO) was reconstituted in sterile 1% ammonium hydroxide, sonicated for 30 s, and incubated at 37°C for 5 d and was used at end concentration of 0.5–1 μM. Typically, cells were treated with Aβ42 for 48 h and U0126 or 0.1% dimethyl sulfoxide (DMSO; for control experiments) was added 30 min before the addition of Aβ42. Typically, fresh media and reagents were added after every 24 h. The transfection of cells with siRNA or plasmid DNA constructs was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) reagent, and manufacturer’s instructions were followed.

**Promoter luciferase assays**

Cortical neurons were transfected with 1 μg of cyclin D1 promoter-luciferase or its mutant plasmid along with 100 ng of β-gal-pCMV plasmid, which was used as an internal control, using Lipofectamine 2000. The first two bases of STAT3 site (Leslie et al., 2006) at base pair –984 (TTCCAGCAA) in the cyclin D1 promoter were changed from TCT to AGT. The luciferase activity was normalized with respect to β-galactosidase activity.

**Brdu labeling and TUNEL assay**

To determine the cell cycle status of neurons upon Aβ42 treatment and to correlate it with neuronal apoptosis, we performed BrdU labeling along with the TUNEL assay. Cells were incubated with 10 μM BrdU in fresh media for 48 h, and a fresh pulse of BrdU was given every 4 h. After fixing and permeabilizing the cells, TUNEL assay was performed using the Dead End Fluorometric TUNEL kit from Promega following the manufacturer’s instructions. After the TUNEL procedure, blocking was done with 2% bovine serum albumin (BSA). The incorporated BrdU was detected using anti-BrdU antibody (Amersham-Pharmacia Biotech), and Hoechst 33342 was used as a nuclear stain. The fluorescently labeled cells were visualized and imaged as described later, and the number of BrdU- and TUNEL-positive cells was determined by counting at least 400 cells from a minimum of five different fields.
Aβ

\[ \downarrow \]

Raf

\[ \downarrow \]

MEK

\[ \downarrow \]

ERK

\[ \downarrow \]

STAT3

\[ \downarrow \]

Cyclin D1

\[ \text{Cdk5} \rightarrow p35 \] (+)

S-phase

\[ \downarrow \]

Apoptosis

**FIGURE 8:** A model for cell cycle reentry-mediated apoptosis. Neurototoxic signals might trigger aberrant activation of the MEK-ERK pathway, resulting in an increase in cyclin D1 levels, which can be by transcription factor STAT3. Cyclin D1 prevents p35-mediated cdk5 activation, which might facilitate the increase in MEK-ERK signaling activity. These events can contribute to cell cycle reentry of neurons, which results in their death.

**Generation of recombinant adenovirus and transduction**

Human cyclin D1-coding region was subcloned in XbaI and HindIII sites of pAdTrack vector. After digestion of this construct with Pmel, the DNA was mixed with pAdEasy vector and electroporated in *Escherichia coli* BJS138. The recombinant clones were digested with *PacI* and transfected in HEK293 cells. The virus was harvested, amplified, and purified using standard procedures. For infection of neuronal cells, ~10 multiplicity of infection was used for transduction, and GFP fluorescence was observed 24–48 h postinfection.

**Immunoblotting and immunofluorescence**

After SDS–PAGE, proteins were transferred to nitrocellulose membrane and immunoblotting was performed. The Super Signal West Pico and Super Signal West Dura extended duration chemiluminescence substrate from Pierce (Rockford, IL) were used, following the manufacturer’s instructions.

For immunofluorescence assays, cells were plated on poly-L-lysine–coated glass coverslips, fixed with 4% paraformaldehyde for 20 min, and permeabilized with 0.2% Tween-20 for 20 min. After blocking with 2% BSA for 12 h at 4°C, incubations with primary antibodies and appropriate secondary antibodies (labeled with Alexa Fluor 594 or 488) were performed for 2–3 h. The nuclei were stained with Hoechst 33342. Cells were visualized using an Axiosmager microscope (Zeiss, Jena, Germany) equipped with RMm camera, and AxioVision software was used for image acquisition and manipulation. Photoshop (Adobe, San Jose, CA) was used for preparing images for illustrations.

**Immunoprecipitation and kinase assay**

From 50 to 70 μg of protein lysate was incubated with ~1 μg of the desired primary antibody for 12 h at 4°C on an end-to-end shaker in a 200-μl reaction volume. Subsequently, 50 μl of protein A+G Sepharose (Amersham-Pharmacia Biotech) was incubated with the antibody–protein complex for 4–6 h at 4°C. The beads were washed and resuspended in 1× kinase assay buffer. The catalytic activity of immunoprecipitated kinase was assayed in a buffer containing 50 mM Tris, pH 7.5, 10 mM magnesium chloride, 1 mM dithiothreitol, and 100 μM [γ-32P]ATP (6000 Ci/mmol) using 2.5 μg of histone H1 or 100 μM of a peptide (PKTPKKAKKL) derived from H1. Reactions were typically carried out for 40 min at 30°C and were terminated by boiling the assay mix in Lamml’s buffer for 5 min at 100°C, followed by SDS–PAGE. Phosphate incorporation in histone H1 was judged by autoradiography of SDS–PAGE gels, and scintillation counting was done to assess phosphorylation of the peptide substrate.

**Image and statistical analysis**

Densitometric analyses were performed using ImageJ software (National Institutes of Health, Bethesda, MD). For statistical comparisons, the data were analyzed by one-way analysis of variance (ANOVA) using Prism software (GraphPad Software, La Jolla, CA). *p* < 0.05 was considered statistically significant.

**ACKNOWLEDGMENTS**

We acknowledge the help rendered by J. Harivaradhan and some experiments. P.K.M and N.K. were supported by DBT postdoctoral fellowships from the Department of Biotechnology, India. P.S. is a Swarnajayanti Fellow and has a National Bioscience Award from the Department of Biotechnology, India. This work was supported by funding from grants from the Department of Biotechnology, India, and the National Institute of Immunology Core.

**REFERENCES**

Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358–1362.

Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH (1997). Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29–42.

Cheung ZH, Gong K, Ip NY (2008). Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. J Neurosci 28, 4872–4877.

Cheung ZH, Ip NY (2004). Cdk5: mediator of neuronal death and survival. Neurosci Lett 361, 47–51.

Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ (2006). ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281, 20315–20325.

Cicerò S, Herrup K (2005). Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci 25, 9658–9668.

Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, Giuffrida Stella AM, Canonico PL, Nicoletti F, Sortino MA (1999). Mitotic signaling by beta-arrestin cell cycle arrest and differentiation. J Biol Chem 278, 20231–20232.

Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003). Aberrant Cdk5 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 278, 20315–20325.

Dhawan R, Tsai LH (2001). A decade of CDK5. Nat Rev Mol Cell Biol 2, 749–759.

Ginty DD, Bonni A, Greenberg ME (1994). Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 77, 713–725.

Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS (1999). Involve}
Guidato S, McLaughlin DM, Grierson AJ, Miller CC (1998). Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem 70, 335–340.

Harper SJ, Wilkie N (2003). MAPKs: new targets for neurodegeneration. Expert Opin Ther Targets 7, 187–200.

Herrup K (2010). The involvement of cell cycle events in the pathogenesis of Alzheimer’s disease. Alzheimers Res Ther 2, 13.

Herrup K, Busser JC (1995). The induction of multiple cell cycle events precedes target-related neuronal death. Development 121, 2385–2395.

Herrup K, Yang Y (2007). Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 8, 368–378.

Hisanaga S, Endo R (2010). Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem 115, 1309–1321.

Hoglinger GU et al. (2007). The p73/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. Proc Natl Acad Sci USA 104, 3585–3590.

Ino H, Chiba T (2001). Cyclin-dependent kinase 4 and cyclin D1 are required for excitoxotoxic-induced neuronal cell death in vivo. J Neurosci 21, 6086–6094.

Klein EA, Assoian RK (2008). Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 121, 3853–3857.

Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH (2001). p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21, 6758–6771.

Krenanburg O, van der Eb AJ, Zantema A (1996). Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15, 46–54.

Lavoe JN, L’Allamain G, Brunet A, Muller R, Pouyssegur J (1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271, 20608–20616.

Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000). Neuropathology and perinatal death. Proc Natl Acad Sci USA 93, 11173–11178.

Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH (2001). p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21, 324–333.

Lance BE, Ginty DD (2002). Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605–623.

Malik B, Currais A, Andres A, Towlson C, Pitsi D, Nunes A, niblock M, Cooper J, Hortobagyi T, Soriano S (2008). Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-1 Alzheimer’s disease brain. Cell Cycle 7, 637–646.

Ng YP, Cheung ZH, Ip NY (2006). STAT3 as a downstream mediator of neurotrophin signaling and functions. J Biol Chem 281, 15636–15644.

Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB (1996). Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93, 11173–11178.

Park DS, Levine B, Ferrari G, Greene LA (1997a). Cyclin dependent kinase 4 and p15 INK4B suppress the neuronal cell cycle by disrupting the E2F1-DP1 complex. Mol Cell Biol 17, 5219–5228.

Sharma P, Veeranna, Sharma M, Amin ND, Sihag RK, Grant P, Ahn N, Kulkarni AB, Pant HC (2002). Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 277, 528–534.

Stanciu M et al. (2000). Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275, 12200–12206.

Subramaniam S, Zingirbel U, Bohlen Und Halbach O, Strelau J, Laliberte C, Kaplan DR, Unsicker K (2004). ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165, 357–369.

Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, Eto K, Ikeda MA (2003). Induction of neuronal cell death in cell cycle regulation: implications in Alzheimer’s disease. Alzheimers Res Ther 2, 13.

Tandon A et al. (2003). Brain levels of CDK5 activator p25 are not increased in Alzheimer’s or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86, 572–581.

Taniguchi S, Fujita Y, Hayashi S, Kakuta A, Takahashi H, Murayama S, Saito TC, Hisanaga S, Iwatsubo T, Hasegawa M (2001). Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 487, 46–50.

Veeranna, Amin ND, Ahn NG, Jaffe H, Winters CA, Grant P, Pant HC (1998). Mitogen-activated protein kinases (Erk1,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J Neurosci 18, 4008–4021.

Wan J, Fu AK, Ip FC, Ng HK, Hugon J, Page G, Wang JH, Lai KO, Wu Z, Ip NY (2010). Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer’s disease. J Neurosci 30, 6873–6881.

Wen Z, Zhong Z, Darnell JE Jr (1995). Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell 82, 241–250.

Xiong Y, Zhang H, Beach D (1992). D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71, 505–514.

Yang Y, Geldmacher DS, Herrup K (2001). DNA replication precedes neuronal cell death evoked by excitotoxic stress: implications for neurodegeneration and its treatment. Neurobiol Aging 21, 771–781.

Patrick GN, Zuikerberg L, Nicola J, de la Monte S, Dikkes P, Tsai LH (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615–622.

Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J (2010). No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc Natl Acad Sci USA 107, 2884–2889.

Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD (1999). Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286, 2358–2361.

Selkoe DJ (1998). The cellular biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Cell Biol 8, 43–48.